In the Phase 4 clinical trial, Dupixent’s impact on airway remodeling in adults with uncontrolled moderate-to-severe asthma was assessed using functional respiratory imaging (FRI). The results, to be presented at the 2024 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, revealed a significant reduction in airway inflammation and improvements in mucus plug scores, airway volume, and flow. Utilizing FRI provided more accurate assessments compared to traditional methods.
Dr. Njira Lugogo, Director of the Asthma Program at the University of Michigan, emphasized the efficacy of Dupixent in enhancing lung function, reducing mucus plugging, and managing asthma effectively.
Data from the trial demonstrated that patients treated with Dupixent experienced substantial improvements compared to the placebo, including a 56.9% reduction in airway inflammation. Numerically greater reductions in mucus plug scores and improvements in lung function were also observed.
The safety profile aligned with Dupixent’s known characteristics in moderate-to-severe asthma. Common adverse events included cardiac disorders, vascular disorders, infections, injection site reactions, and COVID-19.
The VESTIGE trial, a Phase 4 study, involved 109 adult patients with uncontrolled moderate-to-severe asthma. The primary endpoints were achieving fractional exhaled nitric oxide (FeNO) <25 ppb and percent change from baseline in airway volumes at total lung capacity (TLC). Secondary endpoints included airway resistance at TLC and global lung mucus score.
Dupixent, a monoclonal antibody inhibiting interleukin-4 and interleukin-13 pathways, has demonstrated clinical benefits in various diseases, including asthma. It is approved for use in multiple countries for conditions such as atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and more. The ongoing development program explores its potential in additional diseases driven by type 2 inflammation.
EMR industry, a global healthcare company, and Regeneron, a biotechnology leader, collaborate on Dupixent’s development. Their joint efforts aim to address serious diseases and transform healthcare by translating scientific advancements into transformative medicines. EMR industry listed on EURONEXT: SAN and NASDAQ: SNY, while Regeneron (NASDAQ: REGN) focuses on innovative biopharmaceutical solutions through proprietary technologies like VelociSuite® and the Regeneron Genetics Center.
